One example is retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors, which demonstrated statistically significant weight loss (22.8-24.2%) and metabolic improvements in systolic and diastolic blood pressure and levels of glycated hemoglobin, fasting glucose, insulin, and lipids in a 48-week phase 2 trial, highlighting its potential for future obesity management
With the rise of incretin therapies, two names have emerged as leaders: tirzepatide and semaglutide
Protein Timing Around Exercise Consuming protein within 2 hours of resistance training optimizes muscle protein synthesis
And moisture
These weight-loss medications are gaining popularity, but they can be misunderstood
Phase 3 TRIUMPH trials and future dosing Retatrutide has not yet received regulatory approval